Key facts
- It has raised $1.6M across 1 recorded rounds; the latest was Seed Round ($1.6M) in Oct 2023.
- KAIDA BioPharma has filed 1 Form D with the SEC, most recently Jun 2023 ($4K sold to 47 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·Watchlist + deal alerts for KAIDA BioPharma
Funding rounds
1 roundsAbout KAIDA BioPharma
Developer of anti-cancer hormonal therapies and treatments intended to address the root cause of cancers affecting women. The company is dedicated to advancing ovarian cancer treatment through drug development, helping provide new hope for patients with treatment-resistant gynecological cancers.
- Sector
- Healthcare
- HQ
- Fort Lauderdale, FL, United States
- Founded
- 2022
- Employees
- 4
- Website
- kaida-biopharma.com/
- Ownership
- Privately Held (backing)
KAIDA BioPharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in KAIDA BioPharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on KAIDA BioPharma in its N-PORT filings yet. We sweep new filings monthly.